All In Biotech

Drug Trial Radar · NCT07510100

Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

A Phase I/II Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

17

Planned (sponsor's estimate)

Start

May 10, 2026

Primary completion

Aug 31, 2029

Study completion Jan 31, 2030

Sponsor

Sponsor type
Industry
First posted
Apr 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with relapsed and refractory Multiple Myeloma.

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel)Drug

    Eque-cel consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that contains a unique CAR structure with a fully human single-chain variable fragment (scFv).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety endpoint (Part 1)- Adverse Event(AEs)Time frame: up to 2 years from Eque-cel infusion
  2. Safety endpoint (Part 1)-CRSTime frame: up to 2 years from Eque-cel infusion
  3. Safety endpoint (Part 1)-ICANSTime frame: up to 2 years from Eque-cel infusion
  4. Efficacy endpoint (Part 2): Independent Review Committee (IRC)-assessed ORRTime frame: up to 2 years from Eque-cel infusion

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Institute of Science Tokyo Hospital

    Bunkyo-ku, Tokyo, Japan

  • Japanese Red Cross Medical Center

    Shibuya-ku, Tokyo, Japan

  • Nihon University Itabashi Hospital

    tabashi City, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.